BASIC AND CLINICAL STUDIES ON FLEROXACIN

We carried out basic and clinical studies on fleroxacin, a new oral pyridonecarboxylic acid, and obtained the following results. The in vitro antibacterial activity of fleroxacin was tested against 275 strains of clinical isolates of 15 species and compared with those of norfloxacin, ofloxacin, cipr...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 38; no. Supplement2; pp. 390 - 395
Main Authors HIROSE, HIROSHI, OOTSUKA, SADANORI, FUKUI, TOSHIO, OKUI, SHINJI, KATSU, MASATAKA
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1990
Subjects
Fleroxacin
New quinolone
Pyridonecarboxylic acid
Online AccessGet full text

Cover

More Information
Summary:We carried out basic and clinical studies on fleroxacin, a new oral pyridonecarboxylic acid, and obtained the following results. The in vitro antibacterial activity of fleroxacin was tested against 275 strains of clinical isolates of 15 species and compared with those of norfloxacin, ofloxacin, ciprofloxacin, enoxacin, cefixime, cefaclor, ampicillin and minocycline. Fleroxacin and other new pyridonecarboxylic acids were very active against Gram-negative bacilli. We administered fleroxacin to 12 patients with respiratory infections at a dose 200-300mg daily for 7-14 days. The clinical response obtained was excellent in 1 and good in 11 cases. The organisms isolated from two cases, one of Streptococcus pneumoniae and Escherichia coli, were eradicated. Neither side effects nor remarkable worsening of laboratory findings was observed.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.38.Supplement2_390